Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Ocular melanoma].

Thierry Dorval1, Rémi Dendale, Laurence Desjardins

  • 1Département de médecine oncologique, Institut Curie, 75248 Paris Cedex. thierry.dorval@curie.net

La Revue Du Praticien
|February 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Primary uveal diffuse large B-cell lymphoma: A population-based study.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same author

PTCOG Ocular Survey - Perspective on Ocular Particle Therapy: Current Practices and Emerging Trends.

International journal of particle therapy·2026
Same author

Corneal Lymphoma in Humans: First Population-Based Evidence of Occurrence and Clinical Characteristics.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Optimizing bridging radiotherapy prior to CAR-T cell therapy: An evidence-based approach.

Critical reviews in oncology/hematology·2026
Same author

"Hadrontherapy for Life" Symposium, Caen, March 10/11, 2025-Strategy for the Future-Pediatric Tumors.

International journal of particle therapy·2025
Same author

"Hadrontherapy for Life" Symposium, Caen, March 10/11, 2025-Strategy for the Future-Pancreatic Cancer.

International journal of particle therapy·2025
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Ocular melanoma, a rare cancer, has a poor prognosis with large tumors. Radiotherapy is an alternative to surgery, but no adjuvant treatments improve outcomes for this eye cancer.

Area of Science:

  • Oncology
  • Ophthalmology

Context:

  • Ocular melanoma is a rare malignancy with a poor prognosis, particularly when diagnosed at an advanced stage.
  • The incidence in France is approximately 7 per 1,000,000 individuals.
  • Ota's nevus is the only identified risk factor.

Purpose:

  • To review the current understanding and management of ocular melanoma.
  • To highlight the role of radiotherapy as a local treatment option.
  • To discuss the limitations of adjuvant therapies and the need for improved metastatic disease treatment.

Summary:

  • Ocular melanoma presents a significant challenge due to its rarity and poor prognosis in advanced cases.
  • Radiotherapy serves as a viable local treatment alternative to surgery for many patients.

Related Experiment Videos

  • Currently, no adjuvant treatments have proven beneficial, and the management of metastatic ocular melanoma requires further definition.

    • Impact:

    • This review emphasizes the need for further research into effective adjuvant and metastatic treatments for ocular melanoma.
    • It underscores the importance of radiotherapy in the current treatment landscape.
    • Improved understanding and treatment strategies are crucial for enhancing patient outcomes in ocular melanoma.